The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > BUSINESS
BUSINESS
- Nichi-Iko Chief Apologizes for GMP Violations, but Draws Clear Distinction from Kobayashi Kako Case
March 4, 2021
- Mitsubishi Tanabe to Launch US Research Center for CNS Drug Discovery
March 4, 2021
- Takeda to File Moderna Vaccine in Japan This Week
March 4, 2021
- AbbVie Japan to Boost Immunology Reps as It Gears Up for Rinvoq/Skyrizi Label Expansions
March 3, 2021
- Eisai’s Sleep Inducer Dayvigo Approved in Hong Kong
March 3, 2021
- MSD Files Refractory Cough Medicine in Japan
March 3, 2021
- Iwasaki to Bow Out as Chief of Takeda’s Japan Pharma Biz Unit
March 3, 2021
- Mitsubishi Tanabe Licenses Therapeutic App for Depression to DT Axis
March 3, 2021
- Kyowa Kirin Poised to Speed Up Growth with 5 Strategic Launches, Eyes Blockbuster Potential in Eczema Med
March 2, 2021
- Comirnaty Label Updated in Japan to Ease Storage Temperature: Pfizer/BioNTech
March 2, 2021
- Ono, PeptiDream Ink License Pact for Peptide Drug Discovery
March 2, 2021
- Kissei Seeks Approval for C5aR Inhibitor Avacopan in Japan
March 2, 2021
- Idorsia Files Japan NDA for Clazosentan
March 2, 2021
- Online Meeting Promotions Rise on Decrease in Face-to-Face Visits, In-Hospital Seminars in December: Intage
March 2, 2021
- Kyowa Kirin, Harvard Form Strategic Research Alliance
March 1, 2021
- Daiichi Sankyo to Divest 11 Off-Patent Brands to Alfresa
March 1, 2021
- Takeda to Offload 4 Diabetes Meds in Japan to Teijin for 133 Billion Yen
March 1, 2021
- UCB Files Psoriasis Med Bimekizumab for Japan Approval
March 1, 2021
- Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
- Mylan EPD Offering EpiPen for Free to Prep for Possible Vaccine Reactions
February 26, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…